P
Precision BioSciences
A gene editing company specializing in in vivo gene editing with its ARCUS platform
At a glance
- Founded
- 2006
- Headquarters
- Durham, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
- LFLongevity Fund
F-Prime- BVBaxter Ventures
- VPvenBio Partners
- ZGZiegler Group
RA Capital Management- OPOsage University Partners
- AVAmgen Ventures
Series B and later10 investors entered at this stage
Vivo Capital- AIAlexandria Venture Investments
- TCTransformation Capital
- ACAdage Capital
- APArrowMark Partners
Cormorant Asset Management
Franklin Templeton Investments- PAPontifax AgTech
- ACAgent Capital
- BPBrace Pharma
Source: Dealroom Talent Intelligence.
Alumni founders
Former Precision BioSciences employees who went on to found companies, sorted by Dealroom signal score.
CSCumulus Digital SystemsEst. 2018
Matthew KleimanUnited States
TRTraitologyEst. 2022
Fayaz Khazi, Ph.D.United States
ESElo Life SystemsEst. 2021
Derek JantzUnited States
David ThomsonUnited StatesGlobal footprint
team presence
across markets
Patents
38 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Precision BioSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Precision BioSciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.